Former Merck president to lead Reliant

Share this article:
Reliant Pharmaceuticals has named former Merck US human health president Bradley Sheares, as its CEO. Sheares, who will also become a member of Reliant’s board of directors succeeds Ernest Mario, who was CEO since 2003. Mario will continue to serve on the board as chairman. While at Merck, Sheares had commercial responsibility for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases in the US. During his tenure as president, Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, operations management and the development and implementation of corporate policies. Sheares served as VP hospital marketing and sales for US human health prior to his promotion to president, US human health in 2001. He joined Merck in 1987 as a research fellow in the Merck Research Laboratories and moved to the US commercial organization in 1990. Reliant is a privately held company based in Liberty Corner, NJ. Reliant’s portfolio consists of primarily cardiovascular-focused products, with a sales and marketing infrastructure comprised of 825 sales representatives nationwide.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...